The Role of Chemokines in Inflammatory Skin Diseases

2004 ◽  
pp. 191-225
Author(s):  
G. Girolomoni ◽  
S. Pastore ◽  
A. Cavani ◽  
C. Albanesi
Keyword(s):  
Skin Diseases ◽  
Inflammatory Skin Diseases ◽  
Inflammatory Skin

scholarly journals The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

2020 ◽  
Vol 21 (4) ◽  
pp. 1205 ◽  
Author(s):  
Langan ◽  
Recke ◽  
Bokor-Billmann ◽  
Billmann ◽  
Kahle ◽  
...  
Keyword(s):  
Skin Diseases ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Acne Inversa ◽  
Inflammatory Skin Diseases ◽  
Microbial Dysbiosis ◽  
Inflammatory Skin ◽  
Personalised Treatment ◽  
Generation Sequencing

The development of next generation sequencing, coupled with advances in bio-informatics, has provided new insights into the role of the cutaneous microbiome in the pathophysiology of a range of inflammatory skin diseases. In fact, it has even been suggested that the identification of specific skin microbial signatures may not only be useful in terms of diagnosis of skin diseases but they may also ultimately help inform personalised treatment strategies. To date, research investigating the role of microbiota in the development of inflammatory skin diseases has largely focused on atopic eczema and psoriasis vulgaris. The role of the microbiome in Hidradenits suppurativa (HS)—also known as acne inversa—a chronic auto-inflammatory skin disease associated with significant morbidity, has received comparatively little attention. This is despite the fact that antimicrobial therapy plays a central role in the treatment of HS. After briefly outlining the clinical features of HS and current treatment strategies, we move on to review the evidence of microbial dysbiosis in HS pathophysiology. We conclude by outlining the potential for metagenomic studies to deepen our understanding of HS biology but more importantly to identify novel and much needed treatment strategies.

The role of lactobacilli in inhibiting skin pathogens

2021 ◽  
Author(s):  
Lize Delanghe ◽  
Irina Spacova ◽  
Joke Van Malderen ◽  
Eline Oerlemans ◽  
Ingmar Claes ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Skin Diseases ◽  
Skin Barrier Function ◽  
Skin Microbiome ◽  
Inflammatory Skin Diseases ◽  
Cutibacterium Acnes ◽  
Inflammatory Skin ◽  
Skin Conditions

The human skin microbiota forms a key barrier against skin pathogens and is important in modulating immune responses. Recent studies identify lactobacilli as endogenous inhabitants of healthy skin, while inflammatory skin conditions are often associated with a disturbed skin microbiome. Consequently, lactobacilli-based probiotics are explored as a novel treatment of inflammatory skin conditions through their topical skin application. This review focuses on the potential beneficial role of lactobacilli (family Lactobacillaceae) in the skin habitat, where they can exert multifactorial local mechanisms of action against pathogens and inflammation. On one hand, lactobacilli have been shown to directly compete with skin pathogens through adhesion inhibition, production of antimicrobial metabolites, and by influencing pathogen metabolism. The competitive anti-pathogenic action of lactobacilli has already been described mechanistically for common different skin pathogens, such as Staphylococcus aureus, Cutibacterium acnes, and Candida albicans. On the other hand, lactobacilli also have an immunomodulatory capacity associated with a reduction in excessive skin inflammation. Their influence on the immune system is mediated by bacterial metabolites and cell wall-associated or excreted microbe-associated molecular patterns (MAMPs). In addition, lactobacilli can also enhance the skin barrier function, which is often disrupted as a result of infection or in inflammatory skin diseases. Some clinical trials have already translated these mechanistic insights into beneficial clinical outcomes, showing that topically applied lactobacilli can temporarily colonize the skin and promote skin health, but more and larger clinical trials are required to generate in vivo mechanistic insights and in-depth skin microbiome analysis.

Potential role of the skin microbiota in Inflammatory skin diseases

2020 ◽  
Author(s):  
Pan Chen ◽  
Guangwen He ◽  
Jingru Qian ◽  
Yi Zhan ◽  
Rong Xiao
Keyword(s):  
Potential Role ◽  
Skin Diseases ◽  
Skin Microbiota ◽  
Inflammatory Skin Diseases ◽  
Inflammatory Skin

scholarly journals Caveolin as a Universal Target in Dermatology

2019 ◽  
Vol 21 (1) ◽  
pp. 80
Author(s):  
Ilja L. Kruglikov ◽  
Philipp E. Scherer
Keyword(s):  
Transforming Growth Factor Beta ◽  
Glucocorticoid Receptors ◽  
Transforming Growth Factor ◽  
Skin Diseases ◽  
Therapeutic Effects ◽  
Inflammatory Skin Diseases ◽  
Caveolin 1 ◽  
Active Involvement ◽  
Inflammatory Skin

Caveolin-1 is strongly expressed in different dermal and subdermal cells and physically interacts with signaling molecules and receptors, among them with transforming growth factor beta (TGF-β), matrix metalloproteinases, heat shock proteins, toll-like and glucocorticoid receptors. It should therefore be heavily involved in the regulation of cellular signaling in various hyperproliferative and inflammatory skin conditions. We provide an overview of the role of the caveolin-1 expression in different hyperproliferative and inflammatory skin diseases and discuss its possible active involvement in the therapeutic effects of different well-known drugs widely applied in dermatology. We also discuss the possible role of caveolin expression in development of the drug resistance in dermatology. Caveolin-1 is not only an important pathophysiological factor in different hyperproliferative and inflammatory dermatological conditions, but can also serve as a target for their treatment. Targeted regulation of caveolin is likely to serve as a new treatment strategy in dermatology.

Sign in / Sign up

Export Citation Format

Share Document